Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 5/20 | 0.53 |
| ▸ | LTB4R2 | Q9NPC1 | 4/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 4/20 | 0.49 |
| ▸ | CNR2 | P34972 | 4/20 | 0.49 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | THRA | P10827 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7719965 | 0.90 | MEN1 (0.54) | LTB4RLTB4R2ALOX5PTGS2CNR1 | |
| Oxirane SCHEMBL11087690 | 0.86 | SMN1; SMN2 (0.47) | LTB4RLTB4R2ALOX5PTGS2CNR1 | |
| SCHEMBL1846913 | 0.86 | ALOX5 (0.51) | LTB4RLTB4R2ALOX5PTGS2PPARA | |
| SCHEMBL2261717 | 0.85 | THRA (0.47) | LTB4RLTB4R2ALOX5PTGS2CNR1 | |
| SCHEMBL2258436 | 0.85 | THRA (0.47) | LTB4RLTB4R2ALOX5PTGS2CNR1 | |
| SCHEMBL1017777 | 0.84 | THRA (0.54) | LTB4RLTB4R2ALOX5PTGS2CNR1 | |
| SCHEMBL11349780 | 0.84 | THRA (0.54) | LTB4RLTB4R2ALOX5PTGS2CNR1 | |
| SCHEMBL1536977 | 0.84 | THRA (0.54) | LTB4RLTB4R2ALOX5PTGS2CNR1 | |
| SCHEMBL9221890 | 0.84 | THRA (0.54) | LTB4RLTB4R2ALOX5PTGS2CNR1 | |
| SCHEMBL1633596 | 0.84 | LTB4R (0.55) | LTB4RLTB4R2ALOX5PTGS2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2020995-A2 | ZERO-ORDER MODIFIED RELEASE SOLID DOSAGE FORMS | Mallinckrodt Inc. (US) | 2009-02-11 | — | — | EP | claimed |
| WO-2007133583-A2 | ZERO-ORDER MODIFIED RELEASE SOLID DOSAGE FORMS | MALLINCKRODT INC. (US) | 2007-11-22 | — | — | WO | claimed |
| WO-2025080559-A1 | METHODS AND COMPOSITIONS FOR TREATING DRUG OVERDOSE | ENALARE THERAPEUTICS INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| US-20250114370-A1 | METHODS AND COMPOSITIONS FOR TREATING DRUG OVERDOSE | ENALARE THERAPEUTICS INC (US) | 2025-04-10 | — | — | US | disclosed |
| US-20250031718-A1 | NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) COMPOSITIONS, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | SOVIDA SOLUTIONS LTD (GB) | 2025-01-30 | — | — | US | disclosed |
| US-20250032496-A1 | METHODS OF TREATING RESPIRATORY DEPRESSION MODULATED BY A NON-OPIOID AGENT | ENALARE THERAPEUTICS INC (US) | 2025-01-30 | — | — | US | disclosed |
| US-12150461-B2 | Nicotinamide adenine dinucleotide (NAD) compositions, methods of manufacturing thereof, and methods of use thereof | Sovida Solutions Ltd. (GB) | 2024-11-26 | — | — | US | disclosed |
| US-12138267-B2 | Methods of treating respiratory depression modulated by a non-opioid agent | ENALARE THERAPEUTICS INC. (US) | 2024-11-12 | — | — | US | disclosed |
| EP-4456900-A1 | RESPIRATORY STIMULANT PARENTERAL FORMULATIONS | Enalare Therapeutics Inc. (US) | 2024-11-06 | — | — | EP | disclosed |
| US-20240238303-A1 | LARGE-CONDUCTANCE POTASSIUM CHANNEL MODULATORS, COMPOSITIONS THEREOF, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | ENALARE THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240226007-A1 | NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) COMPOSITIONS, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | Sovida Solutions Ltd. (GB) | 2024-07-11 | — | — | US | disclosed |
| EP-1429739-A1 | POLYMER RELEASE SYSTEM | Egalet A/S (DK) | 2004-06-23 | — | — | EP | disclosed |
| EP-1429734-A1 | CONTROLLED RELEASE SOLID DISPERSIONS | Egalet A/S (DK) | 2004-06-23 | — | — | EP | disclosed |
| EP-1429744-A1 | MORPHINE POLYMER RELEASE SYSTEM | Egalet A/S (DK) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003024430-A1 | MORPHINE POLYMER RELEASE SYSTEM | EGALET A/S (DK) | 2003-03-27 | — | — | WO | disclosed |
| WO-2003024426-A1 | CONTROLLED RELEASE SOLID DISPERSIONS | EGALET A/S (DK) | 2003-03-27 | — | — | WO | disclosed |
| WO-2003024429-A1 | POLYMER RELEASE SYSTEM | EGALET A/S (DK) | 2003-03-27 | — | — | WO | disclosed |
| EP-0746310-B1 | CONTROLLED RELEASE COMPOSITION | BM RES AS (DK) | 1998-11-18 | — | — | EP | disclosed |
| EP-0746310-A1 | CONTROLLED RELEASE COMPOSITION | BUKH MEDITEC A/S (DK) | 1996-12-11 | — | — | EP | disclosed |
| WO-1995022962-A1 | CONTROLLED RELEASE COMPOSITION | BM RESEARCH A/S (DK) | 1995-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12138267-B2 | Methods of treating respiratory depression modulated by a non-opioid agent | OPRK1, OPRM1, OPRD1 | LTB4R 686/4885LTB4R2 434/4885ALOX5 730/4885 |
| US-20250032496-A1 | METHODS OF TREATING RESPIRATORY DEPRESSION MODULATED BY A NON-OPIOID AGENT | OPRK1, OPRM1, OPRD1 | LTB4R 686/4885LTB4R2 434/4885ALOX5 730/4885 |
| US-20250114370-A1 | METHODS AND COMPOSITIONS FOR TREATING DRUG OVERDOSE | ADRA2A, ADRA2C, OPRM1 | LTB4R 147/4885LTB4R2 103/4885ALOX5 642/4885 |
| US-20240238303-A1 | LARGE-CONDUCTANCE POTASSIUM CHANNEL MODULATORS, COMPOSITIONS THEREOF, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | KCNN2, KCNN1, KCNN3 | LTB4R 529/4885LTB4R2 360/4885ALOX5 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.